Haemato-oncology clinical trials
Clinical trials are an important part of improving treatment for patients.
Acute myeloid leukaemia (AML) trials
- IDH1 inhibitor study for adults with AML with IDH1 mutation, either relapsed or refractory to conventional treatment or for those unsuitable for conventional treatment at presentation.
- Trial of MDM2 antagonist in combination with intensive chemotherapy for relapsed/refractory AML in fit adults
- AML19 for untreated patients aged 18-60 years with AML. Looking at one vs two doses of gemtuzumab ozogamicin with standard chemotherapy
- AML18 for untreated patients aged over 60 years with AML. Looking at one vs two doses of gemtuzumab ozogamicin with standard chemotherapy
Acute lymphoblastic leukaemia (ALL) trials
- UKALL2011 trial for young adults aged 18-24 years with untreated ALL, looking at different doses of steroids and high dose methotrexate
- MEK inhibitor trial for relapsed/refractory acute lymphoblastic leukaemia with RAS-pathway mutations in adults.